Bio-Gene Technology Ltd. (BGT) AI Stock Analysis

• Market Cap: AU$10.68M
• Dividend Yield: N/A
• Average Volume (3M): 988.87K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.66
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 305,061,100
• 10 Day Avg. Volume: 246,330
• 30 Day Avg. Volume: 988,871
• PEG Ratio: 0.21
• Price to Book (P/B): 2.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: AU$0.03 ▲(70.00% Upside)

The score is held down primarily by weak financial performance—near-zero revenue, ongoing losses, and sustained cash burn—despite low leverage. Technicals show a strong recent move (price above major moving averages and positive MACD), but overbought signals (high RSI and very elevated Stoch) temper the upside. Valuation support is limited because the company is loss-making (negative P/E) and has no stated dividend yield.

Positive Factors

Low leverage / clean balance sheet

Minimal debt and low leverage materially reduce solvency and interest burden for a development-stage biotech. This structural strength gives the company more financial flexibility and lower default risk over the next several quarters while it pursues product or clinical milestones.

Free cash flow improvement in 2025

An FCF improvement year-over-year indicates management progress on cash management or cost control. Sustained improvement in free cash flow would lower reliance on external funding and improve runway, a durable positive if continued across upcoming reporting periods.

Occasional operating cash generation historically

A prior instance of positive operating cash flow shows the business can generate cash under some conditions. That historical capability supports the view that with better commercialization or expense discipline, the company could structurally move toward sustainable operations.

Negative Factors

Revenue collapsed to near-zero

Near-zero revenues eliminate the base for scalable margins and recurring cash generation. Without durable revenue recovery or new commercial products, the firm cannot achieve operating leverage, making long-term viability dependent on funding rather than organic cash flow.

Persistent operating losses and cash burn

Sustained negative operating and free cash flow indicates structural cash burn requiring repeated financing. Over months, this dilutes shareholders, constrains R&D or commercial investment, and increases execution risk if capital markets or funding access tighten.

Shrinking equity / declining net worth

Material declines in equity shrink the balance-sheet buffer that absorbs losses and limits capacity for debt or strategic investment. This structural erosion reduces financial flexibility and raises solvency concerns if losses persist over the coming quarters.

Bio-Gene Technology Ltd. Business Overview & Revenue Model

Company Description

Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

How the Company Makes Money

Bio-Gene Technology Ltd. generates revenue through the commercialization of its proprietary pest control technologies. The company's primary revenue streams include licensing agreements with agricultural and chemical companies that incorporate BGT's technology into their own product lines. Additionally, BGT engages in strategic partnerships to co-develop and distribute its products, allowing for shared revenue and expanded market reach. The company may also receive funding through grants and research collaborations aimed at advancing its technology and expanding its application areas. Sales of its own branded products, if applicable, would also contribute to its earnings.

Bio-Gene Technology Ltd. Financial Statement Overview

Summary

Financials are very weak: revenue has fallen to effectively zero, profitability remains deeply negative with persistent losses, and operating/free cash flow are significantly negative (ongoing cash burn). The main offset is a relatively clean balance sheet with minimal debt, but equity has been shrinking due to continued losses.

Income Statement

The income statement remains very weak: revenue has effectively collapsed to zero in 2025 (annual) after several years of small, volatile sales, and profitability is deeply negative with multi-million losses each year. Margins are consistently negative (gross profit also negative in most years), indicating the business is not yet operating at a commercially sustainable scale. A modest positive is that losses have not accelerated dramatically versus the prior year, but overall the trajectory is unfavorable due to declining revenue and persistent operating losses.

Balance Sheet

The balance sheet is a relative bright spot: debt is minimal (near-zero most years; ~A$51k in 2025) and leverage is low, which reduces financial risk. However, equity has fallen materially from 2022 to 2025, reflecting ongoing losses and capital consumption, and returns on equity are sharply negative. Overall, the company appears lightly levered but shrinking in net worth due to continued losses.

Cash Flow

Cash flow quality is weak: operating cash flow and free cash flow are significantly negative in most years (and strongly negative again in 2023–2025), consistent with a cash-burning development-stage profile. There was one year of positive operating cash flow in 2022, but it was not sustained. A partial positive is that free cash flow improved in 2025 versus 2024, yet the business still requires ongoing funding to cover operating outflows.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	18.32K	149.23K	445.73K	62.61K
Gross Profit	-455.26K	-245.78K	-301.45K	-164.04K	178.59K	-110.59K
EBITDA	-2.03M	-2.58M	-2.97M	-3.14M	-2.92M	-2.85M
Net Income	-2.02M	-2.58M	-2.41M	-3.10M	-2.91M	-2.40M
Balance Sheet
Total Assets	2.15M	2.15M	3.16M	3.84M	7.30M	5.00M
Cash, Cash Equivalents and Short-Term Investments	1.14M	1.14M	2.21M	2.99M	6.34M	3.93M
Total Debt	51.21K	51.21K	0.00	0.00	0.00	0.00
Total Liabilities	522.98K	522.98K	368.45K	613.88K	1.03M	754.57K
Stockholders Equity	1.63M	1.63M	2.79M	3.22M	6.27M	4.25M
Cash Flow
Free Cash Flow	-1.71M	-2.54M	-2.76M	-3.28M	36.67K	-1.83M
Operating Cash Flow	-1.71M	-2.54M	-2.75M	-3.28M	43.52K	-1.83M
Investing Cash Flow	0.00	0.00	-5.70K	0.00	-6.84K	-3.03K
Financing Cash Flow	1.47M	1.47M	1.98M	-75.00K	4.41M	239.88K

Bio-Gene Technology Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 92.14 is Negative, neither overbought nor oversold. The STOCH value of 61.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BGT.

Bio-Gene Technology Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZLD	49 Neutral	AU$7.73M	-2.06	―	―	-99.31%	90.20%
IXC	48 Neutral	AU$9.77M	-20.63	-8.72%	―	―	71.10%
CMB	48 Neutral	AU$13.44M	-2.27	-166.70%	―	―	―
BGT	46 Neutral	AU$10.68M	-2.87	―	―	―	―
HXL	40 Underperform	AU$2.17M	-4.33	-28.49%	―	―	46.43%
1AD	37 Underperform	AU$12.75M	-1.61	-628.72%	―	―	31.87%

Bio-Gene Technology Ltd. Corporate Events

Bio-Gene Builds Momentum as Flavocide and Qcide Move Toward Commercial Stage

Bio-Gene Technology reported strong operational momentum in the December 2025 quarter as it advanced both its Flavocide and Qcide insecticide platforms from foundational R&D into more mature regulatory, formulation and commercial development. The company is prioritising a suite of safety studies and formulation work for Flavocide to support multi-jurisdictional registrations, underpinned by successful pilot-scale manufacturing with Rallis India that provides a clearer pathway to scale-up and future supply agreements. Qcide development continues to benefit from improved plantation yields and biomass processing in Far North Queensland, while its recent approval for listing by the US Organic Materials Review Institute as a botanical pesticide under the USDA National Organic Program strengthens Bio-Gene’s positioning in organic and sustainable agriculture markets and supports additional product formulations. Bio-Gene is also progressing two US Department of Defense-funded Deployed Warfighter Protection programs: a Flavocide-based wearable mosquito protection device that has entered entomological testing with early evidence of efficacy, and a Qcide-based indoor residual spray targeting bed bugs and other pests that is expected to commence following the resolution of administrative delays in the US. Management highlights a refreshed pipeline of eight active product opportunities and expanding international business development, indicating the company is positioned to achieve further technical, regulatory and commercial milestones as demand grows for safer, biologically derived pest control solutions.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

Bio-Gene Advances US Defense-Funded Insecticide Projects

Bio-Gene Technology Ltd. has provided an update on its two projects supported by A$3.0 million in US Department of Defense grants under the Deployed Warfighter Protection program. The Flavocide wearable device project, designed to protect against mosquitoes, is progressing, with initial trials showing promising results. The Qcide indoor spray project, targeting pests like bed bugs and houseflies, is set to commence in 2026 following recent delays. These programs highlight the company’s focus on addressing the rise of insect-borne diseases with innovative, nature-based solutions for both military and civilian use.

Bio-Gene Technology Enhances Disclosure Procedures Following ASX Review

Bio-Gene Technology Limited has completed a review of its continuous disclosure procedures following a directive from the ASX. The review led to the revision of its Communication and Disclosure Policy, the implementation of a comprehensive pre-clearance process for scientific data, and enhanced compliance training for key personnel. These measures aim to ensure that market-sensitive information is disclosed appropriately, maintaining compliance with ASX Listing Rules and enhancing the company’s operational transparency.

Bio-Gene Secures $519,500 R&D Tax Incentive for Innovative Insecticides

Bio-Gene Technology Limited has received a $519,500 research and development tax incentive from the Australian Taxation Office, reflecting its significant R&D expenditure in the 2025 financial year. This incentive supports the development of Bio-Gene’s innovative insecticides, Flavocide® and Qcide®, which are designed to target insects with a new mode of action, enhancing the company’s position in global markets and addressing the challenges of insecticide resistance.

Bio-Gene Technology Successfully Passes All Resolutions at 2025 AGM

Bio-Gene Technology Limited announced that all resolutions were passed at their 2025 Annual General Meeting. This outcome supports the company’s strategic initiatives and governance, potentially strengthening its market position in developing innovative pest management solutions. The approval of resolutions, including the re-election of a director and additional issuance capacity, reflects shareholder confidence and may positively impact future operations.

Bio-Gene Technology Advances Natural Insecticide Development

Bio-Gene Technology Ltd. held its Annual General Meeting on November 19, 2025, where it presented its ongoing efforts in developing natural insecticides. The company emphasizes its commitment to creating innovative pest control solutions with a significant global impact, aiming to strengthen its position in the biotechnology industry and offer valuable alternatives to stakeholders.

Bio-Gene Technology Advances Insecticidal Innovations with Key Developments

Bio-Gene Technology Ltd. reported significant progress in developing and commercializing their insecticidal products, Flavocide® and Qcide®. The company has advanced regulatory studies for Flavocide and achieved pilot-scale manufacturing success, while Qcide has been approved for listing by the Organic Materials Review Institute in the U.S. These developments strengthen Bio-Gene’s position in the pest control market, with ongoing partnerships and grants supporting their growth. The company is poised for further expansion, focusing on regulatory studies, formulation development, and market entry strategies.

Bio-Gene’s Qcide Gains Organic Listing Status in the USA

Bio-Gene Technology Limited announced that its product, Qcide, has been approved by the Organic Materials Review Institute (OMRI) for listing as a Botanical Insecticide under the USDA National Organic Program. This approval enhances Bio-Gene’s market positioning by allowing Qcide to be used in organic and sustainable pest control markets, expanding its potential customer base. The listing supports Bio-Gene’s strategy of offering environmentally responsible products and opens new commercial opportunities in the growing organic agriculture and eco-label markets.